S1 Biopharma, 250 Greenwich St, New York, NY 10007, US

Roivant Sciences is a New York-based biotech company that is revolutionizing the discovery, development, and commercialization of new medicines. Through their innovative model of building agile and focused companies called Vants, Roivant aligns incentives to drive fast and high-quality execution, employing technology across all stages of the drug development process. With a strong focus on autoimmune diseases, Roivant's companies, including Immunovant, Dermavant, and Priovant, are dedicated to developing transformative therapies that have shown promising results in clinical trials. Roivant Sciences has gained recognition for its groundbreaking work, with 10 positive Phase 3 trials since 2019 and 6 FDA approvals. The company's commitment to innovation and its ability to leverage opportunities in the pharmaceutical industry have led to notable successes, such as the $3 billion sale of five of its companies to Sumitomo Pharma. With a broad and differentiated pipeline of investigational drugs, Roivant Sciences is at the forefront of advancing medicines that have the potential to make a significant impact on patient lives.Generated from the website

F & Y Capital

Silver Suites Inc

US Israel Business Counsel

Red Swan Risk